Anika Therapeutics Shares Owned By Institutions vs. Price To Earning

ANIK Stock  USD 16.33  0.10  0.62%   
Based on Anika Therapeutics' profitability indicators, Anika Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Anika Therapeutics' ability to earn profits and add value for shareholders. At this time, Anika Therapeutics' Price To Sales Ratio is quite stable compared to the past year. EV To Sales is expected to rise to 2.59 this year, although the value of Operating Cash Flow Sales Ratio is projected to rise to (0.01). At this time, Anika Therapeutics' Total Other Income Expense Net is quite stable compared to the past year. Interest Income is expected to rise to about 2.3 M this year, although the value of Income Before Tax is projected to rise to (81.1 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.450.6185
Way Down
Very volatile
For Anika Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Anika Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Anika Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Anika Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Anika Therapeutics over time as well as its relative position and ranking within its peers.
  

Anika Therapeutics' Revenue Breakdown by Earning Segment

Check out Trending Equities.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(6.64)
Revenue Per Share
11.139
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.04)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Anika Therapeutics Price To Earning vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Anika Therapeutics's current stock value. Our valuation model uses many indicators to compare Anika Therapeutics value to that of its competitors to determine the firm's financial worth.
JavaScript chart by amCharts 3.21.15FATEKPTIHOOKANIK 010203040 020406080100
Anika Therapeutics is rated second in shares owned by institutions category among its peers. It is number one stock in price to earning category among its peers reporting about  0.46  of Price To Earning per Shares Owned By Institutions. The ratio of Shares Owned By Institutions to Price To Earning for Anika Therapeutics is roughly  2.17 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Anika Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Anika Price To Earning vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Anika Therapeutics

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
91.59 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Anika Therapeutics

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
42.30 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Anika Price To Earning Comparison

100%
Anika Therapeutics is currently under evaluation in price to earning category among its peers.

Anika Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Anika Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Anika Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Anika Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Anika Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-5.9 M-6.2 M
Operating Income-87.6 M-83.3 M
Income Before Tax-85.3 M-81.1 M
Net Loss-82.7 M-78.5 M
Income Tax Expense-2.7 M-2.5 M
Total Other Income Expense Net2.3 M2.4 M
Net Loss-17.1 M-16.2 M
Net Loss-24.6 M-23.3 M
Interest Income2.2 M2.3 M
Net Interest IncomeM2.1 M
Change To Netincome17 M17.8 M
Net Loss(5.64)(5.36)
Income Quality 0.02  0.02 
Net Income Per E B T 0.97  0.95 

Anika Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Anika Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Anika Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Anika Therapeutics' important profitability drivers and their relationship over time.

Use Anika Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anika Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anika Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Anika Therapeutics Pair Trading

Anika Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Anika Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anika Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anika Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anika Therapeutics to buy it.
The correlation of Anika Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anika Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anika Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anika Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Anika Therapeutics position

In addition to having Anika Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Housewares Thematic Idea Now

Housewares
Housewares Theme
Companies making housewares accessories and providing houseware services. The Housewares theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Housewares Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out Trending Equities.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
To fully project Anika Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Anika Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Anika Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Anika Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Anika Therapeutics investors may work on each financial statement separately, they are all related. The changes in Anika Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Anika Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.